Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alnylam Pharmaceuticals Inc ALNY

Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for... see more

Recent & Breaking News (NDAQ:ALNY)

Alnylam to Webcast Conference Call Discussing First Quarter 2017 Financial Results

Business Wire April 27, 2017

Alnylam Reports Final 24-Month Results from Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

Business Wire April 26, 2017

The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran

Business Wire April 26, 2017

Research Reports Initiation on Biotech Stocks -- Tesaro, Alnylam Pharma, Corbus Pharma, and Inovio Pharma

PR Newswire April 12, 2017

High Return Covered Call Trades for Alnylam Pharmaceuticals, Lumber Liquidators, Nutrisystem, 500.Com, and Wix.com!

PR Newswire April 4, 2017

Alnylam to Webcast Presentation at 16th Annual Needham Healthcare Conference

Business Wire March 28, 2017

The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran

Business Wire March 17, 2017

Research Reports Initiation on Biotech Stocks -- Alnylam Pharma, INSYS Therapeutics, Curis, and GenVec

PR Newswire March 9, 2017

Option Trades: Covered Call reports for American Airlines, Alnylam Pharmaceuticals, The Kroger Co, Resolute Energy Corporation and Sage Therapeutics include trade ideas that offer returns of 25% or more!

PR Newswire March 3, 2017

Alnylam Receives European Medicines Agency PRIME Designation for Accelerated Assessment of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias

Business Wire March 1, 2017

Alnylam Acknowledges Rare Disease Day by Highlighting Services to Aid in Rare Disease Diagnosis

Business Wire February 28, 2017

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Business Wire February 27, 2017

Alnylam Pharmaceuticals, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire February 10, 2017

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Period Activity

Business Wire February 8, 2017

Alnylam Presents New Data on Fitusiran at EAHAD

Business Wire February 2, 2017

Ladenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy

Benzinga.com  February 2, 2017

Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2016 Financial Results

Business Wire February 1, 2017

Mid-Afternoon Market Update: Derma Sciences Climbs On Acquisition News; Novadaq Shares Plunge

Benzinga.com  January 11, 2017

Technical Reports on Biotech Stocks -- Biogen, Alnylam Pharma, Cascadian Therapeutics, and Marinus Pharma

PR Newswire January 11, 2017

The Medicines Company Is A Top Pick For 2017

Benzinga.com  January 6, 2017